Bruceantin inhibits multiple myeloma cancer stem cell proliferation

References

• Cuendet M, Pezzuto JM. Antitumor activity of bruceantin: an old drug with new promise. J Nat Prod 2004; 67:269-72; PMID:14987068; http://dx.doi.org/10.1021/np030304+
   PubMed Web of Science ®Google Scholar
• Cuendet M, Christov K, Lantvit DD, Deng Y, Hedayat S, Helson L, McChesney JD, Pezzuto JM. Multiple myeloma regression mediated by bruceantin. Clin Cancer Res 2004; 10:1170-9; PMID:14871997; http://dx.doi.org/10.1158/1078-0432.CCR-0362-3
   PubMed Web of Science ®Google Scholar
• Mata-Greenwood E, Cuendet M, Sher D, Gustin D, Stock W, Pezzuto JM. Brusatol-mediated induction of leukemic cell differentiation and G(1) arrest is associated with downregulation of c-myc. Leukemia 2002; 16:2275-84; PMID:12399973; http://dx.doi.org/10.1038/sj.leu.2402696
   PubMed Web of Science ®Google Scholar
• Ren D, Villeneuve NF, Jiang T, Wu T, Lau A, Toppin HA, Zhang DD. Brusatol enhances the efficacy of chemotherapy by inhibiting the Nrf2-mediated defense mechanism. Proc Natl Acad Sci U S A 2011; 108:1433-8; PMID:21205897; http://dx.doi.org/10.1073/pnas.1014275108
   PubMed Web of Science ®Google Scholar
• Liao LL, Kupchan SM, Horwitz SB. Mode of action of the antitumor compound bruceantin, an inhibitor of protein synthesis. Mol Pharmacol 1976; 12:167-76; PMID:1256442
   PubMed Web of Science ®Google Scholar
• Cuendet M, Gills JJ, Pezzuto JM. Brusatol-induced HL-60 cell differentiation involves NF-kappaB activation. Cancer Lett 2004; 206:43-50; PMID:15019158; http://dx.doi.org/10.1016/j.canlet.2003.11.011
   PubMed Web of Science ®Google Scholar
• Matsui W, Huff CA, Wang Q, Malehorn MT, Barber J, Tanhehco Y, Smith BD, Civin CI, Jones RJ. Characterization of clonogenic multiple myeloma cells. Blood 2004; 103:2332-6; PMID:14630803; http://dx.doi.org/10.1182/blood-2003-09-3064
   PubMed Web of Science ®Google Scholar
• Dalerba P, Cho RW, Clarke MF. Cancer stem cells: models and concepts. Annu Rev Med 2007; 58:267-84; PMID:17002552; http://dx.doi.org/10.1146/annurev.med.58.062105.204854
   PubMed Web of Science ®Google Scholar
• O'Brien CA, Kreso A, Jamieson CH. Cancer stem cells and self-renewal. Clin Cancer Res 2010; 16:3113-20; PMID:20530701; http://dx.doi.org/10.1158/1078-0432.CCR-09-2824
   PubMed Web of Science ®Google Scholar
• Yu Y, Ramena G, Elble RC. The role of cancer stem cells in relapse of solid tumors. Front Biosci 2012; 4:1528-41; PMID:22201973; http://dx.doi.org/10.2741/e478
   PubMedGoogle Scholar
• Abdullah LN, Chow EK. Mechanisms of chemoresistance in cancer stem cells. Clin Transl Med 2013; 2:3; PMID:23369605; http://dx.doi.org/10.1186/2001-1326-2-3
   PubMedGoogle Scholar
• Jakubikova J, Adamia S, Kost-Alimova M, Klippel S, Cervi D, Daley JF, Cholujova D, Kong SY, Leiba M, Blotta S, et al. Lenalidomide targets clonogenic side population in multiple myeloma: pathophysiologic and clinical implications. Blood 2011; 117:4409-19; PMID:21321360; http://dx.doi.org/10.1182/blood-2010-02-267344
   PubMed Web of Science ®Google Scholar
• Matsui W, Wang Q, Barber JP, Brennan S, Smith BD, Borrello I, McNiece I, Lin L, Ambinder RF, Peacock C, et al. Clonogenic multiple myeloma progenitors, stem cell properties, and drug resistance. Cancer Res 2008; 68:190-7; PMID:18172311; http://dx.doi.org/10.1158/0008-5472.CAN-07-3096
   PubMed Web of Science ®Google Scholar
• Nara M, Teshima K, Watanabe A, Ito M, Iwamoto K, Kitabayashi A, Kume M, Hatano Y, Takahashi N, Iida S, et al. Bortezomib reduces the tumorigenicity of multiple myeloma via downregulation of upregulated targets in clonogenic side population cells. PLoS One 2013; 8:e56954; PMID:23469177; http://dx.doi.org/10.1371/journal.pone.0056954
   PubMedGoogle Scholar
• Katoh M, Katoh M. Integrative genomic analyses on HES/HEY family: Notch-independent HES1, HES3 transcription in undifferentiated ES cells, and Notch-dependent HES1, HES5, HEY1, HEY2, HEYL transcription in fetal tissues, adult tissues, or cancer. Int J Oncol 2007; 31:461-6; PMID:17611704; http://dx.doi.org/10.3892/ijo.31.2.461
   PubMed Web of Science ®Google Scholar
• Park JT, Shih IM, Wang TL. Identification of Pbx1, a potential oncogene, as a Notch3 target gene in ovarian cancer. Cancer Res 2008; 68:8852-60; PMID:18974129; http://dx.doi.org/10.1158/0008-5472.CAN-08-0517
   PubMed Web of Science ®Google Scholar
• Dudley DD, Wang HC, Sun XH. Hes1 potentiates T cell lymphomagenesis by up-regulating a subset of notch target genes. PLoS One 2009; 4:e6678; PMID:19688092; http://dx.doi.org/10.1371/journal.pone.0006678
   PubMed Web of Science ®Google Scholar
• Luistro L, He W, Smith M, Packman K, Vilenchik M, Carvajal D, Roberts J, Cai J, Berkofsky-Fessler W, Hilton H, et al. Preclinical profile of a potent gamma-secretase inhibitor targeting notch signaling with in vivo efficacy and pharmacodynamic properties. Cancer Res 2009; 69:7672-80; PMID:19773430; http://dx.doi.org/10.1158/0008-5472.CAN-09-1843
   PubMed Web of Science ®Google Scholar
• Liang CC, Park AY, Guan JL. In vitro scratch assay: a convenient and inexpensive method for analysis of cell migration in vitro. Nat Protoc 2007; 2:329-33; PMID:17406593; http://dx.doi.org/10.1038/nprot.2007.30
   PubMed Web of Science ®Google Scholar
• Parish CR. Fluorescent dyes for lymphocyte migration and proliferation studies. Immunol Cell Biol 1999; 77:499-508; PMID:10571670; http://dx.doi.org/10.1046/j.1440-1711.1999.00877.x
   PubMed Web of Science ®Google Scholar
• Al-Hussaini H, Subramanyam D, Reedijk M, Sridhar SS. Notch signaling pathway as a therapeutic target in breast cancer. Mol Cancer Ther 2011; 10:9-15; PMID:20971825; http://dx.doi.org/10.1158/1535-7163.MCT-10-0677
   PubMed Web of Science ®Google Scholar
• Lobry C, Ntziachristos P, Ndiaye-Lobry D, Oh P, Cimmino L, Zhu N, Araldi E, Hu W, Freund J, Abdel-Wahab O, et al. Notch pathway activation targets AML-initiating cell homeostasis and differentiation. J Exp Med 2013; 210:301-19; PMID:23359070; http://dx.doi.org/10.1084/jem.20121484
   PubMed Web of Science ®Google Scholar
• Abel EV, Kim EJ, Wu J, Hynes M, Bednar F, Proctor E, Wang L, Dziubinski ML, Simeone DM. The Notch pathway is important in maintaining the cancer stem cell population in pancreatic cancer. PLoS One 2014; 9:e91983; PMID:24647545; http://dx.doi.org/10.1371/journal.pone.0091983
   PubMed Web of Science ®Google Scholar
• Grudzien P, Lo S, Albain KS, Robinson P, Rajan P, Strack PR, Golde TE, Miele L, Foreman KE. Inhibition of Notch signaling reduces the stem-like population of breast cancer cells and prevents mammosphere formation. Anticancer Res 2010; 30:3853-67; PMID:21036696; http://dx.doi.org/10.1158/0008-5472.SABCS-106
   PubMed Web of Science ®Google Scholar
• Viatour P, Ehmer U, Saddic LA, Dorrell C, Andersen JB, Lin C, Zmoos AF, Mazur PK, Schaffer BE, Ostermeier A, et al. Notch signaling inhibits hepatocellular carcinoma following inactivation of the RB pathway. J Exp Med 2011; 208:1963-76; PMID:21875955; http://dx.doi.org/10.1084/jem.20110198
   PubMed Web of Science ®Google Scholar
• Klinakis A, Lobry C, Abdel-Wahab O, Oh P, Haeno H, Buonamici S, van De Walle I, Cathelin S, Trimarchi T, Araldi E, et al. A novel tumour-suppressor function for the Notch pathway in myeloid leukaemia. Nature 2011; 473:230-3; PMID:21562564; http://dx.doi.org/10.1038/nature09999
   PubMed Web of Science ®Google Scholar
• Osipo C, Golde TE, Osborne BA, Miele LA. Off the beaten pathway: the complex cross talk between Notch and NF-kappaB. Lab Invest 2008; 88:11-7; PMID:18059366; http://dx.doi.org/10.1038/labinvest.3700700
   PubMed Web of Science ®Google Scholar
• Saito N, Fu J, Zheng S, Yao J, Wang S, Liu DD, Yuan Y, Sulman EP, Lang FF, Colman H, et al. A high Notch pathway activation predicts response to gamma secretase inhibitors in proneural subtype of glioma tumor-initiating cells. Stem Cells 2014; 32:301-12; PMID:24038660; http://dx.doi.org/10.1002/stem.1528
   PubMed Web of Science ®Google Scholar
• Debeb BG, Cohen EN, Boley K, Freiter EM, Li L, Robertson FM, Reuben JM, Cristofanilli M, Buchholz TA, Woodward WA. Pre-clinical studies of Notch signaling inhibitor RO4929097 in inflammatory breast cancer cells. Breast Cancer Res Treat 2012; 134:495-510; PMID:22547109; http://dx.doi.org/10.1007/s10549-012-2075-8
   PubMed Web of Science ®Google Scholar
• Ratajczak M, Tarnowski M, Staniszewska M, Sroczynski T, Banach B. Mechanisms of cancer metastasis: involvement of cancer stem cells? Minerva Med 2010; 101:179-91; PMID:20562805
   PubMed Web of Science ®Google Scholar
• Eyler CE, Rich JN. Survival of the fittest: cancer stem cells in therapeutic resistance and angiogenesis. J Clin Oncol 2008; 26:2839-45; PMID:18539962; http://dx.doi.org/10.1200/JCO.2007.15.1829
   PubMed Web of Science ®Google Scholar
• Bao S, Wu Q, Sathornsumetee S, Hao Y, Li Z, Hjelmeland AB, Shi Q, McLendon RE, Bigner DD, Rich JN. Stem cell-like glioma cells promote tumor angiogenesis through vascular endothelial growth factor. Cancer Res 2006; 66:7843-8; PMID:16912155; http://dx.doi.org/10.1158/0008-5472.CAN-06-1010
   PubMed Web of Science ®Google Scholar
• Folkins C, Shaked Y, Man S, Tang T, Lee CR, Zhu Z, Hoffman RM, Kerbel RS. Glioma tumor stem-like cells promote tumor angiogenesis and vasculogenesis via vascular endothelial growth factor and stromal-derived factor 1. Cancer Res 2009; 69:7243-51; PMID:19738068; http://dx.doi.org/10.1158/0008-5472.CAN-09-0167
   PubMed Web of Science ®Google Scholar
• Calabrese C, Poppleton H, Kocak M, Hogg TL, Fuller C, Hamner B, Oh EY, Gaber MW, Finklestein D, Allen M, et al. A perivascular niche for brain tumor stem cells. Cancer Cell 2007; 11:69-82; PMID:17222791; http://dx.doi.org/10.1016/j.ccr.2006.11.020
   PubMed Web of Science ®Google Scholar
• Petrelli A, Valabrega G. Multitarget drugs: the present and the future of cancer therapy. Expert Opin Pharmacother 2009; 10:589-600; PMID:19284362; http://dx.doi.org/10.1517/14656560902781907
   PubMed Web of Science ®Google Scholar
• Medema JP. Cancer stem cells: the challenges ahead. Nat Cell Biol 2013; 15:338-44; PMID:23548926; http://dx.doi.org/10.1038/ncb2717
   PubMed Web of Science ®Google Scholar
• Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 1983; 65:55-63; PMID:6606682; http://dx.doi.org/10.1016/0022-1759(83)90303-4
   PubMed Web of Science ®Google Scholar
• Issa ME, Hall SR, Dupuis SN, Graham CL, Jakeman DL, Goralski KB. Jadomycins are cytotoxic to ABCB1-, ABCC1-, and ABCG2-overexpressing MCF7 breast cancer cells. Anticancer Drugs 2014; 25:255-69; PMID:24231527; http://dx.doi.org/10.1097/CAD.0000000000000043
   PubMed Web of Science ®Google Scholar
• Klco JM, Spencer DH, Lamprecht TL, Sarkaria SM, Wylie T, Magrini V, Hundal J, Walker J, Varghese N, Erdmann-Gilmore P, et al. Genomic impact of transient low-dose decitabine treatment on primary AML cells. Blood 2013; 121:1633-43; PMID:23297133; http://dx.doi.org/10.1182/blood-2012-09-459313
   PubMed Web of Science ®Google Scholar
• Li M, Liu X, Sun X, Wang Z, Guo W, Hu F, Yao H, Cao X, Jin J, Wang PG, et al. Therapeutic effects of NK-HDAC-1, a novel histone deacetylase inhibitor, on collagen-induced arthritis through the induction of apoptosis of fibroblast-like synoviocytes. Inflammation 2013; 36:888-96; PMID:23549599; http://dx.doi.org/10.1007/s10753-013-9616-0
   PubMed Web of Science ®Google Scholar
• Thayanithy V, Park C, Sarver AL, Kartha RV, Korpela DM, Graef AJ, Steer CJ, Modiano JF, Subramanian S. Combinatorial treatment of DNA and chromatin-modifying drugs cause cell death in human and canine osteosarcoma cell lines. PLoS One 2012; 7:e43720; PMID:22957032; http://dx.doi.org/10.1371/journal.pone.0043720
   PubMedGoogle Scholar
• Koressaar T, Remm M. Enhancements and modifications of primer design program Primer3. Bioinformatics 2007; 23:1289-91; PMID:17379693; http://dx.doi.org/10.1093/bioinformatics/btm091
   PubMed Web of Science ®Google Scholar
• Untergasser A, Cutcutache I, Koressaar T, Ye J, Faircloth BC, Remm M, Rozen SG. Primer3–new capabilities and interfaces. Nucleic Acids Res 2012; 40:e115; PMID:22730293; http://dx.doi.org/10.1093/nar/gks596
   PubMed Web of Science ®Google Scholar
• Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001; 25:402-8; PMID:11846609; http://dx.doi.org/10.1006/meth.2001.1262
   PubMed Web of Science ®Google Scholar
• Nakatsu MN, Hughes CC. An optimized three-dimensional in vitro model for the analysis of angiogenesis. Methods Enzymol 2008; 443:65-82; PMID:18772011; http://dx.doi.org/10.1016/S0076-6879(08)02004-1
   PubMed Web of Science ®Google Scholar
• Carpentier G. Angiogenesis Analyzer [Internet]. Faculté des Sciences et Technologie, Université Paris Est Creteil, Val de Marne, France [ Updated 2013 December 30; Cited 2016 May 30]. Available from: https://imagej.nih.gov/ij/macros/toolsets/Angiogenesis%20Analyzer.txt
   Google Scholar